Mayo Clinic Minute: Long-term health risks of gestational diabetes
Gestational diabetes?happens when a woman's?body can?t make enough insulin during pregnancy. Most women with gestational diabetes deliver healthy babies; however, there are risks of future complications. Women with gestational diabetes have an increased risk of heart disease and stroke, according to a?recent study? Dr. Margaret Dow, an OB-GYN at Mayo Clinic, says,"Cardiovascular risk is quite [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 13, 2018 Category: Databases & Libraries Source Type: news

'Well done' red meat linked to liver disease, diabetes risk factor
(Reuters Health) - People who eat lots of processed and red meat are at increased risk of developing chronic liver disease and insulin resistance, a diabetes risk factor - especially if they like their steak well done, an Israeli study suggests. (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Pharmacists Can Help With DM Management Via Telemedicine
THURSDAY, April 12, 2018 -- Pharmacist use of telemedicine is a promising vehicle for improving patient management of diabetes, according to an article published in Drug Topics. Noting that 50 percent of all drug errors involve insulin and that 97... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2018 Category: Pharmaceuticals Source Type: news

Physicians Among Diabetes Activists Protesting Insulin Prices Physicians Among Diabetes Activists Protesting Insulin Prices
Washington event was among several planned rallies decrying the high cost of insulin and calling for systemic health care change.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 11, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

JDRF tackles insulin consistency, potency at U.S. pharmacies
JDRF is teaming up with the American Diabetes Association and the Leona M. and Harry B. Helmsley Charitable Trust to support research evaluating the consistency and potency of insulin purchased at retail pharmacies in the U.S. The group called for proposals from analytical laboratories to assess the activity of insulin in vials and cartridges, looking for variations that could pose a safety risk for people with diabetes. Get the full story at our sister site, Drug Delivery Business News.   The post JDRF tackles insulin consistency, potency at U.S. pharmacies appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Pharmaceuticals Research & Development American Diabetes Assn. Juvenile Diabetes Research Foundation (JDRF) Source Type: news

A Guide to Biosimilars and Follow-On Biologics of Insulin A Guide to Biosimilars and Follow-On Biologics of Insulin
Find out what there is to know about biosimilars and follow-on biologics of insulin. How do they differ from standard generics?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Video: How diabetes affects your blood sugar
Diabetes affects your body's ability to use sugar for energy. See how diabetes, blood sugar and insulin are related. (Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - April 10, 2018 Category: Consumer Health News Source Type: news

Tandem inks distro deal in Italy for insulin pump
Tandem Diabetes Care (NSDQ:TNDM) has signed a distribution deal with Movi SpA to commercialize Tandem’s t:slim X2 insulin pump in Italy. The San Diego, Calif.-based company said today that Movi is slated to run sales, marketing and customer training for Tandem’s products in Italy, according to the terms of the agreement. Get the full story at our sister site, Drug Delivery Business News. The post Tandem inks distro deal in Italy for insulin pump appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 9, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Distribution Drug-Device Combinations Pharmaceuticals Wall Street Beat tandemdiabetes Source Type: news

Toujeo (Insulin Glargine Injection for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 9, 2018 Category: Drugs & Pharmacology Source Type: news

Roundup: FDA digital health clearances and news in Q1 2018
In the last quarter the FDA gave the nod to 10 digital health devices. Innovations that aimed to help diabetes management were popular, ranging from the first integrated continuous glucose monitor, which was put out by Dexcom, to Glooko ’s insulin titration tool.  (Source: mobihealthnews)
Source: mobihealthnews - April 6, 2018 Category: Information Technology Source Type: news

How to Succeed in the Diabetes Device Space
  Last month, private equity firm Platinum Equity offered Johnson & Johnson $2.1 billion for J&J's LifeScan Inc. blood glucose monitoring unit. This comes after plans to shutter its Animas insulin pump subsidiary. Although J&J plans to close the doors on its diabetes business, other companies thrive…or at least break even. Success in this competitive space takes flexibility, a commitment to the long game and a deeper commitment to the patients themselves. Unfortunately, diabetes devices have plenty of potential customers. More than 100 million Americans now live with diabetes or prediabetes, and mo...
Source: MDDI - April 5, 2018 Category: Medical Devices Authors: Heather R. Johnson Tags: Business Source Type: news

Diabetes type 2 diet: Avoid this popular sandwich filler to control blood sugar
TYPE 2 diabetics are warned to steer clear of dangerous trans fats, as they increase insulin resistance, belly fat and inflammation. The fats are hiding in some of your favourite sandwich fillers. (Source: Daily Express - Health)
Source: Daily Express - Health - April 5, 2018 Category: Consumer Health News Source Type: news

Cell cycle heterogeneity directs the timing of neural stem cell activation from quiescence
In this study, however, we demonstrate that quiescent NSCs (qNSCs) are arrested in either G2 or G0. G2-G0 heterogeneity directs NSC behavior: G2 qNSCs reactivate before G0 qNSCs. In addition, we show that the evolutionarily conserved pseudokinase Tribbles (Trbl) induces G2 NSCs to enter quiescence by promoting degradation of Cdc25String and that it subsequently maintains quiescence by inhibiting Akt activation. Insulin signaling overrides repression of Akt and silences trbl transcription, allowing NSCs to exit quiescence. Our results have implications for identifying and manipulating quiescent stem cells for regenerative p...
Source: ScienceNOW - April 5, 2018 Category: Science Authors: Otsuki, L., Brand, A. H. Tags: Development, Neuroscience reports Source Type: news

Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
Sigilon's Afibromer technology will be used to encapsulate insulin-producing cells for the potential treatment of type 1 diabetes Sigilon to receive upfront payment of $63 million and undisclosed equity investment INDIANAPOLIS and CAMBRIDGE, Mass., A... Biopharmaceuticals, Endocrinology, Licensing Eli Lilly, Sigilon Therapeutics, encapsulated cell therapies, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 4, 2018 Category: Pharmaceuticals Source Type: news

Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes
Eli Lilly (NYSE:LLY) plans to put $473 million on the table to fund a collaboration with Cambridge, Mass.-based startup Sigilon Therapeutics, the insulin-maker reported today. The goal of the newly-established partnership is to develop encapsulated cell therapies to treat Type I diabetes. Get the full story at our sister site, Drug Delivery Business News. The post Eli Lilly inks $63m deal with Sigilon to develop encapsulated cell therapies for diabetes appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Funding Roundup Pharmaceuticals Research & Development Wall Street Beat Eli Lilly & Co. sigilontherapeutics Source Type: news

Finding Good Candidates for Risk-Sharing Arrangements
Continued from Part I that discusses the tools device manufacturers can use to manage risk How to find good candidates? Not all devices are created equal. But how can device manufacturers identify the low-hanging fruit for a risk-sharing arrangement? Needless to say, the more characteristics a product has that are associated with successful risk-sharing arrangements, the more such an arrangement is likely to succeed. To illustrate, in Exhibit 1, we chart a select number of risk-sharing arrangements established since 2015 along two key dimensions: product effectiveness and time needed to observe expected outcomes. The findi...
Source: MDDI - April 3, 2018 Category: Medical Devices Authors: Harry Liu and Christine Chen Tags: Contract Manufacturing Design Source Type: news

Insulin Requirement Increases With Parity in Pregnant Diabetics Insulin Requirement Increases With Parity in Pregnant Diabetics
Insulin requirement increases with parity in pregnant women with type 1 diabetes, researchers from Denmark report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 3, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Bydureon Add-On Therapy in T2D OK'd by FDA
(MedPage Today) -- For patients not achieving glycemic control with basal insulin (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 3, 2018 Category: Endocrinology Source Type: news

AstraZeneca ’ s once-weekly diabetes drug wins expanded FDA approval
AstraZeneca (NYSE:AZN) said today that the FDA approved its extended-release formulation of exenatide, Bydureon, for use as an add-on therapy to basal insulin in adults with Type II diabetes. The company’s once-weekly GLP-1 injectable was first approved in the U.S. in 2012. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat AstraZeneca plc Source Type: news

FDA Approves Bydureon (exenatide extended-release) for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
April 3, 2018 AstraZeneca today announced the US Food and Drug Administration (FDA) has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes (T2D) with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 3, 2018 Category: Drugs & Pharmacology Source Type: news

Where are the Low-Hanging Fruits for Device Manufacturers?
(Part One of a Two-Part Series) As the U.S. healthcare system becomes increasingly value-oriented, a relatively new phenomenon is occurring—the increased use of risk-sharing arrangements between manufacturers and providers or payers, where payments for devices are tied to patient outcomes and/or financial metrics. In early 2018, leading medical-device manufacturer Medtronic announced it had a risk-sharing arrangement in place with more than 1,000 hospitals for its TYRX technology for cardiac implants in the U.S., an increase of about 700 hospitals over six months. Medtronic has also started five other simil...
Source: MDDI - April 2, 2018 Category: Medical Devices Authors: Harry Liu and Christine Chen Tags: Business Source Type: news

Myocardial Protection by GIK in On-Pump Cardiac Surgery Myocardial Protection by GIK in On-Pump Cardiac Surgery
Can pretreatment with an IV infusion of glucose-insulin-potassium attenuate postcardiotomy ventricular dysfunction and improve outcome in patients undergoing open-heart surgery?Anesthesia & Analgesia (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 2, 2018 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

GLP-1 and Insulin and Microvasculature and Conduit Artery GLP-1 and Insulin and Microvasculature and Conduit Artery
A new study examines the impacts of GLP-1 and insulin on muscle microvasculature and conduit artery in healthy adults.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 2, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Insulin pumps not cost  effective if no clinical need
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2018 Category: Drugs & Pharmacology Source Type: news

Dexcom CEO on ‘ treading new ground ’ with G6 glucose monitor
Kevin Sayer sold his first glucose sensor in 1994. More than twenty years later, the chief executive of Dexcom (NSDQ:DXCM) still believes that glucose-monitoring technology can transform the way patients manage their diabetes. This week, Dexcom won FDA approval for its latest continuous glucose monitor. The G6 system is the first of the company’s that does not require a finger-prick for calibration and is also cleared as “fully interoperable” with other medical devices, like insulin pumps and decision support software. “This Gen 6 system brings to fruition all that I envisioned when I first saw...
Source: Mass Device - March 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Dexcom Eli Lilly & Co. Insulet tandemdiabetes Source Type: news

EndoBreak: High-Capacity Insulin Pen OK'd; 13 Cancers; Smart Socks
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - March 30, 2018 Category: Urology & Nephrology Source Type: news

Bigfoot Steps Up Its Funding Game with Abbott & #039;s Help
The little company with a big name – and big ambitions in the diabetes space – just closed a big financing round. Milpitas, CA-based Bigfoot Biomedical has now raised more than $90 million, including the $55 million series B round that it just closed. The company also added Abbott to its list of investors, which doesn't come as a complete surprise, given that the two companies began working together last summer to develop diabetes management systems, integrating the Abbott FreeStyle Libre glucose-sensing technology as the centerpiece for glucose monitoring capabilities within Bigfoot's ecosystem of in...
Source: MDDI - March 29, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Courtney Lias and Stayce Beck paved the way for an automated insulin dosing system to receive FDA approval years earlier than expected, helping to make a groundbreaking new device for diabetes management available for Americans with Type 1 diabetes #WomensHistoryMonthpic.twitter.com/t1EyVQAh8t
Courtney Lias and Stayce Beck paved the way for an automated insulin dosing system to receive FDA approval years earlier than expected, helping to make a groundbreaking new device for diabetes management available for Americans with Type 1 diabetes #WomensHistoryMonth pic.twitter.com/t1EyVQAh8t (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - March 28, 2018 Category: Medical Devices Authors: ( at FDADeviceInfo) Source Type: news

Bigfoot brings Series B total to $55m with new investment from Abbott
Reeling in an $18 million add-on to the $37 million Series B that it reported last year, Bigfoot Biomedical touted today that it has raised over $90 million in total funding since the Milpitas, Calif.-based company first launched. Investments from Abbott (NYSE:ABT), which has an established partnership with Bigfoot, and other new and existing investors, brought the Series B round total to $55 million. The company said it plans to use its newly-acquired funds to support the development and clinical evaluation of its closed-loop automated insulin delivery system, Bigfoot Loop, and its connected ...
Source: Mass Device - March 28, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Funding Roundup Pharmaceuticals Wall Street Beat Abbott Bigfoot Biomedical Source Type: news

Dexcom Scores Nod for First Interoperable CGM
Dexcom is once again shaking up in the continuous glucose monitoring (CGM) market. The San Diego-based company has received the green light from the FDA to market the Dexcom G6 CGM System, a device that is interoperable with other automated insulin dosing  systems. FDA said this is the first device that has been given approval to work with other compatible technologies. The agency also said its decision classifies Dexcom’s CGM as a less stringent medical device and enables a speedier review for similar future systems. “The ability of this device to work with different types of compatible devices gives pati...
Source: MDDI - March 28, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

FDA Okays New Interoperable Continuous Glucose Monitor FDA Okays New Interoperable Continuous Glucose Monitor
The Dexcom G6 is the first to integrate with numerous other monitoring and insulin delivery devices.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA approves DexCom's glucose monitoring system
(Reuters) - The U.S. Food and Drug Administration on Tuesday approved DexCom Inc's monitoring system to check blood sugar levels in children and adults suffering from diabetes, which can be used along with devices such as insulin pumps. (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Toujeo(R) Max SoloStar(R)
Max SoloStar holds more insulin than any other long-acting insulin pen New pen can potentially reduce the number of injections for people who need more long-acting insulin and lower copay costs BRIDGEWATER, N.J., March 27, 2018 -- (Healthcare Sales &... Biopharmaceuticals, Drug Delivery, FDA Sanofi, Toujeo, insulin glargine, insulin pen, insulin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2018 Category: Pharmaceuticals Source Type: news

Sanofi ’ s high-capacity insulin pen wins FDA nod
Sanofi (NYSE:SNY) reported today that its Toujeo Max SoloStar high-capacity insulin pen won FDA approval and will be available in the third quarter of this year. The new device holds 900 units of long-acting insulin and delivers 160 units/mL of Toujeo insulin glargine in each injection, the insulin-maker touted. Get the full story at our sister site, Drug Delivery Business News. The post Sanofi’s high-capacity insulin pen wins FDA nod appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 27, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Sanofi-Aventis Source Type: news

Closed-Loop Insulin System Works in Kids as Young as 7 Years Closed-Loop Insulin System Works in Kids as Young as 7 Years
Medtronic's MiniMed 670G hybrid closed-loop insulin delivery system improves glycemic outcomes in children with type 1 diabetes as young as age 7, according to a study funded by the manufacturer.Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 27, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

FDA Approves Toujeo (insulin glargine) Max SoloStar
BRIDGEWATER, N.J., March 27, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Sanofi's Toujeo (insulin glargine 300 Units/mL) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 27, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves label update to Novo Nordisk ’s Tresiba diabetes drug
The FDA approved Novo Nordisk‘s (NYSE:NVO) request to include heart health data on the label of its Tresiba insulin degludec product. The Danish insulin-maker evaluated its Type II diabetes drug in a 7,637-patient trial, assessing the therapy for cardiovascular safety compared to insulin glargine. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves label update to Novo Nordisk’s Tresiba diabetes drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news

FDA approves inclusion of data from safety outcomes trial in the Tresiba(R) label
The data showed that Tresiba® (insulin degludec injection) U-100 had no increased risk of MACE compared to insulin glargine U-100 in patients with type 2 diabetes and ASCVD1 Tresiba® U-100 becomes the first and only long-acting insulin to have d... Biopharmaceuticals, Endocrinology, Cardiology, FDA Novo Nordisk, Tresiba, insulin degludec, insulin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 26, 2018 Category: Pharmaceuticals Source Type: news

Influence of diabetes on tissue healing in orthopedic injuries - Stolarczyk A, Sarzy ńska S, Gondek A, Cudnoch-Jędrzejewska A.
Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from the defective action or secretion of insulin. Chronic hyperglycemia can lead to the damage, dysfunction and failure of various organs. In the context of complications o... (Source: SafetyLit)
Source: SafetyLit - March 26, 2018 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

vTv Therapeutics reaches milestone in study of its diabetes drug
VTv Therapeutics Inc. has completed a portion of a study examining at how one of the biopharmaceutical company's drug therapies addresses Type 1 diabetes. VTv Therapeutics (NASDAQ: VTVT) partnered with JDRF on the study, which looks at the company's therapy "TTP399" as an oral treatment for Type 1 diabetes, including whether it is tolerated by people with the condition when administered as an add-on to insulin therapy. The part of the study that was recently completed was the Phase 1b assessment,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 26, 2018 Category: Pharmaceuticals Authors: Jessica Seaman Source Type: news

Liver enzyme may be link between abdominal fat and diabetes
A study, published inNature, reports that targeting enzyme, DPP4, in the liver can reduce adipose inflammation, lower insulin resistance and decrease blood sugar in mice.Medical News Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - March 26, 2018 Category: Endocrinology Source Type: news

Medical News Today: Is this how abdominal fat leads to diabetes?
New research shows that an enzyme produced by the liver causes inflammation in the abdominal fat, raising the risk of insulin resistance and diabetes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2018 Category: Consumer Health News Tags: Obesity / Weight Loss / Fitness Source Type: news

Potatoes GOOD for diabetics? Study finds prebiotic from potatoes actually reduces insulin resistance
(Natural News) Diabetics and pre-diabetics are often told to avoid potatoes due to being relatively high on the glycemic index (GI). But, as a new study demonstrated, potatoes may actually be more beneficial than detrimental. MSPrebiotic, a natural, digestion-resistant starch made from potato (Solanum tuberosum) extract was found to have a positive impact on gut... (Source: NaturalNews.com)
Source: NaturalNews.com - March 24, 2018 Category: Consumer Health News Source Type: news

NIH study finds islet transplants improve quality of life for people with Type I diabetes
A Phase III trial funded by the National Institutes of Health found that quality of life for people with type I diabetes improved dramatically following transplantation of insulin-producing pancreatic islets, according to data published this week in the journal Diabetes Care. The 48-patient trial involved participants with hypoglycemia unawareness, a condition that renders them unable to sense when their blood sugar drops to a dangerous level. Get the full story at our sister site, Drug Delivery Business News. The post NIH study finds islet transplants improve quality of life for people with Type I diabetes appeared f...
Source: Mass Device - March 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Research & Development National Institutes of Health (NIH) Source Type: news

Japan approves Novo Nordisk ’ s once-weekly Type II diabetes drug
The Japanese Ministry of Health, Labor and Welfare gave Novo Nordisk (NYSE:NVO) the green light to market its once-weekly type II diabetes drug, Ozempic, Reuters reported today. The pharma company’s drug, semaglutide, is a glucagon-like peptide-1 analog that mimics an intestinal hormone to trigger insulin production in people with diabetes. Get the full story at our sister site, Drug Delivery Business News. The post Japan approves Novo Nordisk’s once-weekly Type II diabetes drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - March 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Wall Street Beat AstraZeneca plc Eli Lilly & Co. Novo Nordisk Source Type: news

Blitzing belly fat lowers your risk of diabetes and heart issues
While scores of papers have found this to be the case, few have been able to explain what makes belly fat riskier for insulin resistance than any other type of body fat, until this Columbia study. (Source: the Mail online | Health)
Source: the Mail online | Health - March 21, 2018 Category: Consumer Health News Source Type: news

Piedmont Healthcare expands use of Glytec ’ s insulin dosing decision software
Piedmont Healthcare, which uses Glytec‘s insulin therapy tech at three of its hospitals, plans to expand use of the eGlycemic Management System to all of its acute care facilities. Glytec’s software features evidence-based insulin dosing decision support, surveillance of blood glucose values to identify patients at risk of low and high blood sugar, real-time alerts to warn healthcare workers of an emergency, as well as robust analytics, according to the company. Get the full story at our sister site, Drug Delivery Business News. The post Piedmont Healthcare expands use of Glytec’s insulin dosing deci...
Source: Mass Device - March 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Hospital Care Pharmaceuticals Wall Street Beat Glytec Source Type: news

Islet cell transplants improve type 1 diabetes of participants in trial
Type 1 diabetics' low blood glucose levels improved dramatically with transplantation of insulin-producing islets to their pancreas, according a trial. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 21, 2018 Category: Consumer Health News Source Type: news

' Bionic Pancreas' OK for Very Young T1D Patients
(MedPage Today) -- Improved glycemic outcomes with closed-loop insulin pump system in 7-year-olds (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 21, 2018 Category: Cardiology Source Type: news

Red and Processed Meats Linked to Liver Woes
The researchers also looked at how meats were cooked. They found that cooking meat at high temperatures for a long time -- such as grilling, broiling or frying -- was associated with about double the risk of insulin resistance. (Source: WebMD Health)
Source: WebMD Health - March 20, 2018 Category: Consumer Health News Source Type: news